AskBio Inc, a gene therapy subsidiary of Bayer AG, has named Laura Sepp-Lorenzino to the board. Dr Sepp-Lorenzino brings over 30 years of executive and academic experience across modalities and therapeutic areas, including gene therapy and editing. She is currently scientific advisor, executive vice president, at Intellia Therapeutics, where she was formerly chief scientific officer. Dr Sepp-Lorenzino will support AskBio in moving clinical programmes through and beyond Phase 2 and advancing the next pre-clinical candidate. Her other board positions include Taysha Gene Therapies and the Alliance for Regenerative Medicine. She holds a PhD in biochemistry from New York University, US, has received several awards for women in science and is on the editorial boards of several scientific journals.
AskBio announced the appointment on 8 April 2025.
Copyright 2025 Evernow Publishing Ltd.